Contact Us

Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nephrotoxicity Analysis Service

The kidney is the important organ of the human body, and is the main way to get drugs and their metabolites out of the body. The kidney is particularly vulnerable to drugs, which can have a direct toxic effect on the kidney or cause kidney damage through an allergic reaction. Some drugs, especially aminoglycosides, have shown some drug-induced nephrotoxicity. Most drug candidates must be tested for toxicity to vital organs such as the heart, liver and kidney. Early toxicity screening can eliminate unsafe drug candidates early, avoid showing toxicity in the late stage of development, and reduce unnecessary expenditure. Therefore, it is important to evaluate drug safety before human trials. Nephrotoxicity can be detected early in the corresponding cell or animal model, providing important reference for drug development.

With scientific and technological services as the starting point, Creative Biolabs has a sound basic experimental platform, advanced experimental equipment, professional technical team, standard operating procedures, high-quality cooperation platform and strong scientist network, providing professional scientific and technological cooperation and transformation service guidance for domestic and foreign researchers and institutions. Through high-content screening, MTT/cck8 and other methods, we can provide customers with a comprehensive drug toxicity detection service, including renal toxicity.

We provide but are not limited to:

  • Neutrophil gelatinase-associated lipocalin (NGAL). In ischemic or nephrotoxic renal injury, NGAL is expressed in large quantities by the kidneys and is released into the urine and plasma. NGAL levels increased within 2 hours of injury, making it an early and sensitive biomarker for kidney injury. Because NGAL is a biomarker that reflects renal toxicology, it is ideal as a biomarker for drug safety and efficacy testing. As a biomarker, NGAL has two uses in drug development: (1) The drug safety marker; (2) The drug efficacy marker.
    • Early determination of drug safety - negative screening. NGAL is primarily used as a safety indicator for the outcome of nephrotoxicity or acute kidney injury (AKI) following treatment with candidate drugs. NGAL Rapid ELISA Kit can quickly detect the nephrotoxicity of drugs.
    • Early identification of drug efficacy - positive screening. NGAL can also be used to screen drug candidates for the prevention or experimental treatment of acute kidney injury (AKI). This type of study using an animal model with an ischemia-reperfusion or known nephrotoxic agents -induced AKI pattern to screen for the ability of candidate drugs to prevent, improve or reverse injury by observing NGAL levels.

    Creative Biolabs can rapidly and reliably diagnose acute kidney injury by using NGAL ELISA Kit, NGAL Rapid ELISA Kit, MBL Oligomer ELISA Kit, gc-globulin (Actin Free) ELISA Kit and other experimental techniques.

  • Nephrotoxicity PCR Array. In animal models of toxic reactions, those genes that consistently rise or fall can serve as potential markers for predicting adverse clinical reactions. Nephrotoxicity PCR chips can be used to study the expression of 84 key genes that can serve as potential molecular markers of nephrotoxicity. The chip contains differentially expressed genes caused by known nephrotoxic drugs. Using real-time quantitative PCR, researchers can reliably and simultaneously detect genes associated with nephrotoxicity.
  • Zebra fish. The animal model is time-consuming and labor-intensive. The cell model is onefold and the primary culture is difficult. Comparatively speaking, zebra fish is a simple, efficient, easy to control, highly sensitive and less compound dosage in vivo nephrotoxicity evaluation model. The primary kidney of zebra fish is composed of a pair of nephrons, two glomerulus and anterior renal tubules. Using this advantage, Creative Biolabs establish an evaluation model of zebra fish kidney toxicity, which is tested by evaluating glomerular filtration rate. This model is successfully verified by positive drugs, including aristolochia acid, acyclovir, vancomycin and irbetartan. Renal toxicity can be assessed in two ways:
    • Incidence of renal edema. Since zebrafish are transparent, renal edema can be clearly observed.
    • Glomerular filtration rate. A fluorescent marker can be injected into zebrafish. After a period of time, normal zebrafish can expel the fluorescent marker from the body, while zebrafish with impaired glomerular filtration function cannot. The excretion of the fluorescent marker can reflect the function of zebrafish kidney.

The popular services:

  • Under the precondition of keeping the integrity of the cell structure and function, high-content screening (HCS) can research the influence of samples on cell morphology, growth, differentiation, migration, apoptosis, metabolic pathway and signal transduction. HCS obtain a large number of genes, proteins and other cellular components related information in a single experiment, determining the biological activity and potential toxicity.
  • High-throughput screening (HTS) is an experimental tool carrier in the form of microplates, which can realize automatic operation. HTS can detect tens of millions of samples at the same time, obtaining corresponding database to support operation, with trace, fast, sensitive and accurate characteristics.

The Creative Biolabs HCS/HTS platform is equipped with a variety of advanced equipment and data processing system to achieve the full automation of high-content/throughput screening, providing strong support for a reliable study of nephrotoxicity.

Advantages of our nephrotoxicity detection services:

  • Reducing drug research and development costs.
  • Customized comprehensive solution.
  • One-stop analysis platform.
  • Continuous technological innovation.


  1. Wu H, et al. Drug-Induced Nephrotoxicity: Pathogenic Mechanisms, Biomarkers and Prevention Strategies. Curr Drug Metab. 2018, 19(7):559–567.
  2. Izzedine H. Drug nephrotoxicity. Nephrol Ther. 2018, 14(3):127–134.
  3. Shuai Z L, et al. Review of high-content screening applications in toxicology. Archives of Toxicology, 2019, 93(12): 3387-3396.

*For Research Use Only. Not for use in diagnostic procedures.

Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.